MLX-7006

Company to Highlight a Unique All-Oral Dual-Therapy for Metabolic Health in Clinical Development, Featuring a Novel Oral GLP-1 Agonist and a Skeletal Muscle-Selective AMPK Activator LEHI, Utah - January 9, 2026 — Biolexis Therapeutics , a clinical-stage biotechnology company pioneering an all-oral combination therapy for metabolic disease, today announced it will present at the 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2026. The presentation will spotlight Biolexis' differentiated strategy to overcome the scalability, durability, and access limitations of current injectable weight loss therapies, including two clinical-stage programs: • BLX-7006 - A first-in-human oral small-molecule allosteric GLP-1 receptor agonist based on a new chemical scaffold with Phase 1 data demonstrating a clean safety pro predictable once-daily pharmacokinetics, preparing to advance to Phase 2 trials. • BLX-0871 - A first-in-class oral γ3 isoform-selective AMPK activator designed to preserve lean muscle mass and metabolic durability, entering Phase 1 trials in January 2026. BLX-7006: Redefining GLP-1 Access BLX-7006 binds a distinct allosteric pocket on the GLP-1 receptor, enabling cooperative activation while reducing receptor desensitization, a key limitation of peptide-based therapies. As a small molecule, BLX-7006 offers transformative advantages: oral administration without fasting requirements, no cold-chain logistics, and a significantly lower cost-of-goods, enabling global-scale deployment. BLX-0871: Solving the Muscle Loss Problem Current GLP-1 therapies produce significant weight loss, but up to 40% is lean mass, driving metabolic adaptation and weight regain. BLX-0871 selectively activates γ3-containing AMPK complexes enriched in skeletal muscle, engaging exercise-associated metabolic pathways while sparing cardiac isoforms. This results in preserved lean mass, enhanced glucose uptake, and sustained metabolic rate. The All-Oral Combination Advantage Biolexis is developing the only all-oral dual combination therapy for metabolic diseases in clinical trials. By pairing GLP-1-mediated appetite suppression with muscle-selective AMPK activation, the company aims to deliver sustainable weight loss with preserved muscle mass and metabolic function. “The GLP-1 revolution has proven we can treat obesity, but current injectable peptides have significant limitations,” said David J. Bearss, PhD, Co-founder and Chairman of Biolexis Therapeutics. “Biolexis overcomes these limitations by combining a novel oral GLP-1 agonist with a muscle-selective AMPK activator to combat the current shortcomings of obesity treatments. We’re not just helping patients lose weight, we’re helping them keep it off by preserving muscle mass, promoting healthier long-term weight loss.” Conference Availability Biolexis’ executive team will be available throughout the J.P. Morgan Healthcare Conference for meetings with potential strategic partners and institutional investors. These discussions will focus on Phase 2 clinical plans, combination development strategy, and potential partnership opportunities. About Biolexis Therapeutics Biolexis Therapeutics is a clinical-stage biotechnology company headquartered in Lehi, Utah, building an all-oral therapy for metabolic disease. By combining novel small-molecule GLP-1 receptor agonism with isoform-selective AMPK activation, Biolexis is developing sustainable metabolic therapies with fewer restrictions, allowing for global deployment. For more information, visit Forward-Looking Statements This press release contains forward-looking statements within the meaning of applicable securities laws. These statements involve risks and uncertainties that could cause actual results to differ materially, including risks related to clinical trial outcomes, regulatory approvals, and market conditions. Biolexis undertakes no obligation to update forward-looking statements. Contact: Kyle Medley kmedley@biolexistx.com 453-893-5473